Biomark Diagnostics Inc. (CSE:BUX)
Canada
· Delayed Price · Currency is CAD 0.4750
-0.0050 (-1.04%)
At close: Dec 5, 2025
Biomark Diagnostics Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 0.12 | 0.15 | 0.16 | 0.15 | 0.04 | - | Upgrade
|
| Revenue Growth (YoY) | -21.89% | -5.52% | 6.34% | 249.38% | - | - | Upgrade
|
| Gross Profit | 0.12 | 0.15 | 0.16 | 0.15 | 0.04 | - | Upgrade
|
| Selling, General & Admin | 0.75 | 0.74 | 0.75 | 0.73 | 0.65 | 0.9 | Upgrade
|
| Research & Development | 0.58 | 0.7 | 0.65 | 0.55 | 0.5 | 0.12 | Upgrade
|
| Operating Expenses | 1.87 | 2.2 | 1.87 | 1.99 | 1.33 | 1.03 | Upgrade
|
| Operating Income | -1.74 | -2.05 | -1.71 | -1.84 | -1.28 | -1.03 | Upgrade
|
| Interest Expense | -0.04 | -0.06 | -0.06 | -0.11 | -0.04 | - | Upgrade
|
| Interest & Investment Income | 0.02 | 0 | 0 | 0 | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.06 | -0 | 0 | - | -0 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.17 | 0.18 | 0.34 | 0.11 | -0.13 | -0.06 | Upgrade
|
| EBT Excluding Unusual Items | -1.65 | -1.93 | -1.43 | -1.84 | -1.45 | -1.1 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0 | Upgrade
|
| Pretax Income | -1.65 | -1.93 | -1.43 | -1.84 | -1.45 | -1.09 | Upgrade
|
| Net Income | -1.65 | -1.93 | -1.43 | -1.84 | -1.45 | -1.09 | Upgrade
|
| Net Income to Common | -1.65 | -1.93 | -1.43 | -1.84 | -1.45 | -1.09 | Upgrade
|
| Shares Outstanding (Basic) | 98 | 91 | 85 | 83 | 78 | 73 | Upgrade
|
| Shares Outstanding (Diluted) | 98 | 91 | 85 | 83 | 78 | 73 | Upgrade
|
| Shares Change (YoY) | 10.10% | 6.67% | 2.97% | 6.22% | 6.31% | 2.82% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | Upgrade
|
| Free Cash Flow | -1.42 | -1.1 | -0.99 | -0.92 | -1.26 | -0.81 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -1413.46% | -1327.45% | -1046.96% | -1198.95% | -2922.50% | - | Upgrade
|
| Profit Margin | -1340.24% | -1249.73% | -874.52% | -1200.21% | -3309.36% | - | Upgrade
|
| Free Cash Flow Margin | -1151.45% | -711.12% | -604.65% | -599.20% | -2875.13% | - | Upgrade
|
| EBITDA | -1.73 | -2.03 | -1.7 | -1.83 | -1.28 | -1.03 | Upgrade
|
| D&A For EBITDA | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| EBIT | -1.74 | -2.05 | -1.71 | -1.84 | -1.28 | -1.03 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.